JPH0564745B2 - - Google Patents
Info
- Publication number
- JPH0564745B2 JPH0564745B2 JP14625285A JP14625285A JPH0564745B2 JP H0564745 B2 JPH0564745 B2 JP H0564745B2 JP 14625285 A JP14625285 A JP 14625285A JP 14625285 A JP14625285 A JP 14625285A JP H0564745 B2 JPH0564745 B2 JP H0564745B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- protein
- test piece
- dye
- molybdenum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 238000012360 testing method Methods 0.000 claims description 42
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 239000002738 chelating agent Substances 0.000 claims description 19
- 229910052750 molybdenum Inorganic materials 0.000 claims description 19
- 239000011733 molybdenum Substances 0.000 claims description 19
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 18
- -1 aluminum ions Chemical class 0.000 claims description 17
- 239000002250 absorbent Substances 0.000 claims description 12
- 230000002745 absorbent Effects 0.000 claims description 12
- KUQNCHZOCSYKOR-UHFFFAOYSA-N 1,1-dioxospiro[2,1$l^{6}-benzoxathiole-3,9'-xanthene]-3',4',5',6'-tetrol Chemical group O1S(=O)(=O)C2=CC=CC=C2C21C1=CC=C(O)C(O)=C1OC1=C(O)C(O)=CC=C21 KUQNCHZOCSYKOR-UHFFFAOYSA-N 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- 235000006408 oxalic acid Nutrition 0.000 claims description 8
- 229910052684 Cerium Inorganic materials 0.000 claims description 7
- 229910052782 aluminium Inorganic materials 0.000 claims description 7
- 229910021645 metal ion Inorganic materials 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- HGPSVOAVAYJEIJ-XDHOZWIPSA-N 2-[(e)-(3,4-dihydroxyphenyl)-(3-hydroxy-4-oxoniumylidenecyclohexa-2,5-dien-1-ylidene)methyl]benzenesulfonate Chemical compound C1=CC(=O)C(O)=C\C1=C(C=1C(=CC=CC=1)S(O)(=O)=O)/C1=CC=C(O)C(O)=C1 HGPSVOAVAYJEIJ-XDHOZWIPSA-N 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- MLIREBYILWEBDM-UHFFFAOYSA-N anhydrous cyanoacetic acid Natural products OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 claims description 6
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- JYXGIOKAKDAARW-UHFFFAOYSA-N N-(2-hydroxyethyl)iminodiacetic acid Chemical compound OCCN(CC(O)=O)CC(O)=O JYXGIOKAKDAARW-UHFFFAOYSA-N 0.000 claims description 4
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 claims description 4
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 3
- 230000002485 urinary effect Effects 0.000 claims description 3
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 claims description 2
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 claims description 2
- 229940005657 pyrophosphoric acid Drugs 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 description 43
- 210000002700 urine Anatomy 0.000 description 33
- 238000005259 measurement Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 239000000975 dye Substances 0.000 description 11
- 239000000123 paper Substances 0.000 description 11
- 238000000691 measurement method Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005470 impregnation Methods 0.000 description 5
- 108010044091 Globulins Proteins 0.000 description 4
- 102000006395 Globulins Human genes 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 4
- 239000011609 ammonium molybdate Substances 0.000 description 4
- 235000018660 ammonium molybdate Nutrition 0.000 description 4
- 229940010552 ammonium molybdate Drugs 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229920000915 polyvinyl chloride Polymers 0.000 description 4
- 239000004800 polyvinyl chloride Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 108010074605 gamma-Globulins Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010008428 Chemical poisoning Diseases 0.000 description 1
- 206010018352 Globulinuria Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000819999 Nymphes Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- QPMIVFWZGPTDPN-UHFFFAOYSA-N Tetrabromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C(C(Br)=C(Br)C(Br)=C2Br)=C2S(=O)(=O)O1 QPMIVFWZGPTDPN-UHFFFAOYSA-N 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- QFXYYBXMARTXHI-UHFFFAOYSA-N bromopyrogallol red Chemical compound O1S(=O)(=O)C2=CC=CC=C2C21C1=CC(Br)=C(O)C(O)=C1OC1=C(O)C(O)=C(Br)C=C21 QFXYYBXMARTXHI-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- VGBWDOLBWVJTRZ-UHFFFAOYSA-K cerium(3+);triacetate Chemical compound [Ce+3].CC([O-])=O.CC([O-])=O.CC([O-])=O VGBWDOLBWVJTRZ-UHFFFAOYSA-K 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- PHLYOKFVXIVOJC-UHFFFAOYSA-N gallein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C(O)=C1OC1=C(O)C(O)=CC=C21 PHLYOKFVXIVOJC-UHFFFAOYSA-N 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VLAPMBHFAWRUQP-UHFFFAOYSA-L molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Description
〔産業上の利用分野〕
本発明は、蛋白、特に尿蛋白の測定用試験片に
関する。
〔発明の背景〕
健康な人でも毎日尿中に20〜80mgの蛋白質を排
泄するといわれているが、この排泄される蛋白質
は通常粒子が小さく糸球体を通過し易いアルブミ
ンが主体である。一方、溶血がひどく血漿内に赤
血球のヘモグロビンが多量に遊出しこれが腎糸球
体から漏れたり、あるいは腎臓や尿路に炎症があ
る場合などには白血球を尿中に放出するので、グ
ロブリンを主体とする尿蛋白となる。尿蛋白は一
般に次のような場合に高値となり腎疾患の重要な
指針となる。
(1) 急性、および慢性腎炎、ネフローゼ。
(2) 心不全による腎の鬱血、その他。
(3) 熱性蛋白尿。
(4) 化学薬品中毒、細菌性中毒。
(5) 白血病、紫斑病。
(6) 狭窄、結石 腫瘍による尿管の閉塞。
(7) 脳腫瘍、癲癇、その他中枢神経系疾患、精神
感動。
(8) 膿、血液、精液などの混入。
(9) 卵など分子量の小さい蛋白質の多量摂取。
(10) 激しい運動、熱い湯又は冷水に長時間つかつ
た後に現われる一過性のもの。
(11) 体位性および若年性蛋白尿。
現在、一般に行なわれている尿蛋白測定法とし
ては下記の如き方法がある。
(1) スルホサルチル酸法(鋭敏度 0.002%)
透明尿4〜5ml+スルホサリチル酸20W/V%
溶液2〜3滴→白色混濁又は沈澱を生ずれば蛋白
陽性。
(2) 煮沸試験法(鋭敏度 約0.005%)
透明尿5mlを1〜2分間煮沸し、混濁を生じた
ならば熱時5%酢酸、又は70%硝酸を1〜3滴添
加し、混濁が不変又は増加した場合は蛋白陽性。
(3) Robers法(鋭敏度 0.003%)
試料と硫酸マグネシウムの硝酸溶液とを等容混
合し境界面に白輪が生ずれば蛋白陽性。
(4) 試験紙法(鋭敏度 0.03%)
ブロムフエノールブルーあるいはテトラブロム
フエノールブルー等のPH指示薬がタンパクの存在
により、アルカリ側の呈色をするタンパク誤差法
を利用。
(5) クマシーブリリアントブルー法
(鋭敏度 0.001%)
色素と蛋白の結合による高感度測定法で、試料
50μ+CBB−G250溶液3ml→595nmの吸光度を
測定。
(6) トリクロル酢酸沈澱によるビウレツト法
検体(原尿)2ml+蒸留水2ml+トリクロル酢
酸(10%溶液)混和後3000rpmで5分以上遠心後
上清を捨てる。沈澱にビウレツト試薬(NaOH4
%、酒石酸カリウムナトリウム結晶4.5%、
CuSO4・5H2O 0.5%、ヨウ化カリウム0.5%)
2ml+蒸留水2ml混和後、37℃、30分間加温し
540nmで比色。
これらの内、スルホサリチル酸法、煮沸試験
法、Robers法は、比濁法又はそれに準ずる方法
で多量の試料を必要とし、しかも定量分析に適用
するには精度的に限度がある。一方クマシーブリ
リアントブルー法は比色法であるが、検量線が湾
曲することや、セル、試験管等の汚染があること
などから多数検体を連続処理するにはそぐわない
ものとされている。
又、トリクロル酢酸沈澱によるビウレツト法
は、沈澱分離操作を必要とするので操作が繁雑で
あり実用的ではない。
又、蛋白誤差法を利用した試験紙法は非常に簡
便であり、広く普及しているが、感度が低く、特
に正常、異常の境界域での判定が困難であり、さ
らにアルブミンに対しグロブリンの呈色が極めて
低いという欠点があつた。
一方、分析化学Vol.32 379〜386(1983)によれ
ば、ピロガロールレツドとモリブデン酸塩混合物
(PR−モリブデン錯体)に蛋白(アルブミン)を
添加するとλmaxが長波長側にシフトし蛋白を高
感度で比色定量することが可能であるとの記載が
ある。しかしながら、文献記載の試薬に試料とし
て健常人の尿(スルホサリチル酸法で陰性)を使
用して蛋白濃度を測定すると殆んどの検体で吸光
度が試薬ブランクより低値となり蛋白濃度として
負値が算出される現象に遭遇する。従つて、この
方法をそのまま人尿検体を試料とした尿蛋白の測
定に適用することは到底不可能であり、尿蛋白の
簡便で且つ高感度、高精度の測定法が渇望されて
いる現状にある。
〔発明の目的〕
本発明は、上記した如き現状に鑑み、簡便で且
つ高感度、高精度の尿蛋白測定法を提供すべく、
モリブデン酸塩と、モリブデンと錯体を形成し蛋
白の存在で波長がシフトする色素とを用いる尿試
験紙法による尿蛋白測定法の実用化を目的として
なされたものである。
〔発明の構成〕
本発明は、モリブデン酸塩と、モリブデン
と錯体を形成し、さらに蛋白の存在で波長がシフ
トする色素と、モリブデンと結合するキレート
剤、又は前記色素とは反応せず、試料中に共存が
予想されるシユウ酸、クエン酸、リン酸及びこれ
らの塩と結合し得る金属イオンと、緩衝剤とか
ら成る蛋白測定用組成物を含浸させた吸収性担体
から成る蛋白測定用試験片の発明である。
即ち、本発明者らはモリブデンと錯体を形成
し、更に蛋白の存在で波長がシフトする色素を用
いる尿蛋白の測定法の実用化について鋭意研究を
重ねた結果、色素及びモリブデンを主成分とする
測定試薬中に予めモリブデンと結合し得るキレー
ト剤を添加するか、又は前記色素とは反応せず、
試料中に共存が予想されるシユウ酸、クエン酸、
リン酸、及びこれらの塩と結合し得る金属イオン
を添加することにより、その目的を達成し得るこ
と及びかかる試薬組成物を含浸させた担体(試薬
保持片)から成る試験片を用いることにより簡
便、且つ高感度、高精度の尿蛋白測定が可能とな
ることを見出し本発明を完成するに到つた。
本発明は、ピロガロールレツド、ピロカテコー
ルバイオレツト等の色素がモリブデンと錯体を形
成し、この錯体が蛋白と結合して極大吸収波長が
長波長側にシフトすることを利用して蛋白、特に
尿蛋白の測定を試験紙法により行うに当り、試料
中に存在し、呈色をうすくする原因となるキレー
ト剤、即ち、有機酸又は/及びリン酸塩類、又は
これらと同じ作用をもつキレート剤を予め含浸試
薬中に添加しておくか、又は前記色素とは反応せ
ず、試料中に共存が予想されるシユウ酸、クエン
酸、リン酸、及びこれらの塩と結合し得る金属イ
オンを含浸試薬中に添加しておくことにより、正
常尿の呈色がうすくなる現象を回避し、極めて高
精度に尿中蛋白の測定を行うことを可能とすると
共に、グロブリンをアルブミンとほぼ同程度の感
度で測定することを可能ならしめたものである。
即ち、ピロガロールレツド、ピロカテコールバ
イオレツト等の色素類は、モリブデンと錯体を形
成して着色する(或いは着色が増す)が、モリブ
デンと結合力のある他のキレート剤が共存する
と、モリブデンの一部はこれら色素類との結合か
ら離れ他のキレート剤と結合し、この為盲検の呈
色がうすくなる。含浸試薬中にキレート剤を徐々
に添加していくと盲検の呈色は添加量に従つて
徐々にうすくなり、ある添加量を超えると試料に
由来するキレート剤が混入されてきてももはやそ
れ以上に呈色がうすくなる現象は殆んど認められ
なくなりうすい呈色を示さなくなる。
又同様に含浸試薬中にアルミニウムイオン、セ
リウムイオン等を添加すると試料中のキレート剤
(シユウ酸、クエン酸、リン酸等)はアルミニウ
ムイオン、セリウムイオン等を結合してモリブデ
ンとは結合しなくなり(又は結合する割合が少な
くなり)呈色がうすくなるのを回避することがで
きる。従つて、測定組成物中に予めモリブデンと
結合し得るキレート剤、若しくはアルミニウムイ
オン、セリウムイオン等の金属イオンを添加して
おくことにより、正常尿の呈色がうすくなりすぎ
る現象は解消されると同時に、モリブデンと結合
するキレート剤やアルミニウムイオン、セリウム
イオン等を含んだ試薬を用いて高濃度の蛋白含有
試料について測定しても正確な測定が可能とな
る。
本発明者らは、モリブデンと錯体を形成し、更
に蛋白の存在で波長がシフトする色素を使用した
尿蛋白の測定法の於て、これまで解明されていな
かつた正常尿が負値を示す原因について究明し、
その解決方法として、本発明者らは独自の知見に
基づいて上記結論を導き出し本発明に到達した。
本発明の方法によれば、正常尿の呈色がうすく
なりすぎることのまく、定量性、再現性共に良好
である。
更に、本発明の蛋白測定用試験片は高感度であ
る為、従来のタンパク誤差法を用いた試験紙法で
は判定が極めて不明瞭であつた正常と異常の境界
域(蛋白濃度10〜30mg/dl)が明瞭となり、判定
が容易となつた。
また、従来のタンパク誤差法ではアルブミンに
対する、グロブリンの呈色は極めて低かつたが、
本発明の方法では、グロブリンはほぼアルブミン
と同程度呈色し、従来の試験紙法では見逃してい
た可能性のあるグロブリン尿の検知が可能となつ
た。
本発明に於て用いられるキレート剤としては、
エチレンジアミン四酢酸(EDTA)、ヒドロキシ
エチルエチレンジアミン三酢酸(EDTA−OH)、
エチレンジアミン二酢酸(EDDA)、イミノニ酢
酸(IDA)、ニトリロプロピオン酸(NTP)、ニ
トリロ三酢酸(NTA)、ヒドロキシエチルイミ
ノ二酢酸(HIDA)、クエン酸、酒石酸、シユウ
酸、1−ヒドロキシエタン−1,1−ジホスホン
酸、ピロリン酸、ヘキサメタリン酸、トリポリリ
ン酸、メタリン酸等が挙げられる。これらは単独
でも2種類以上の混合物で用いても良く、又含浸
液調製時溶解法性を増す為にこれらをナトリウ
ム、カリウム、リチウム等のアルカリ金属塩やア
ンモニウム塩等として塩の型で添加してもよい。
その添加量は添加するキレート剤により異なる
が、通常0.001〜1%の濃度で1乃至数回に分け
紙、不織布等の吸収性担体に含浸させる。
又本発明に使用可能な金属イオンとしては、ア
ルミニウムイオン、セリウムイオン(、)等
が適当である。本発明に於て使用可能な色素とし
ては、モリブデンの存在下アルブミンと定量的に
錯体を形成するピロガロールレツド(PR)、ブロ
ムピロガロールレツド、ピロカテコールバイオレ
ツト(PV)、o−ヒドロキシヒドロキニンフタレ
ン、ガレイン等の色素が挙げられる。これら色素
類の使用量は通常含浸液濃度として0.0005〜0.1
%であり、1乃至数回に分けて紙あるいは不織
布等の吸収性担体に含浸させればよい。又これら
色素類と錯体を形成するモリブデンは、通常モリ
ブデン酸のアルミニウム塩、若しくはアルカリ金
属塩として用いられるがこれらに限定されるもの
ではない。その使用量は例えばモリブデン酸塩の
場合、モリブデン酸イオンの濃度として通常含浸
液中濃度として0.0005〜0.1%程度が用いられ、
1乃至数回に分け吸収性担体に含浸させることが
出来る。
本発明の蛋白測定用試験片に於て用いられる吸
収性担体としては紙、セルローズ、化学繊維、合
成樹脂製織布および不織布等通常の測定用試験片
に於て用いられる吸収性担体が例外なく用いられ
る。又、吸収性担体を保持する支持体としては、
ガラス繊維、およびポリ塩化ビニル、ポリスチレ
ン、ポリビニルアセタール、アセチルセルロー
ス、ニトロセルロース、ポリ塩化ビニリデン、ポ
リプロピレン等の合成高分子化合物などが挙げら
れ、これらのシートあるいはコーテイングした厚
紙等が好ましく用いられる。
これら吸収性担体及び支持体の大きさ、寸法等
については特に制約がなく、通常用いられている
測定用試験片に於ける吸収性担体及び支持体の大
きさ、寸法に準じたものを用いれば足りる。ま
た、吸収性担体への薬剤の含浸方法、及び吸収性
担体の支持体への接着方法に関しては、通常の測
定用試験片に於て行われているいずれの方法で行
つてもよく、特別な方法は必要としない。
表1に本発明の方法に於けるキレート剤の添加
効果を示す。尚、測定条件は下記の通りである。
測定条件
検体尿
蛋白陰性(スルホサリチル酸法による)尿A,
B,Cに、人アルブミン又は人γ−グロブリンを
20mg/dlとなるように添加したものを検体とし
た。
含浸液
ピロガロールレツドを250mg/、モリブデン
酸ナトリウムを300mg/の濃度になるように
0.5Mグリシン−塩酸緩衝液(PH2.5)に溶解し
た。
試験片の作製法
上記含浸液に種々のキレート剤を表中の濃度添
加し、これを厚さ0.4mmの紙に含浸させ乾燥し
た。このようにして得られた試験紙を5mm角に切
断し、両面接着テープを用いて5mm×8cmのポリ
塩化ビニルシートの一端に貼り付け試験片とし
た。
測定方法
本試験片を検体尿に瞬時浸漬して、これを含浸
させ60秒後の呈色を測定した。呈色は、陰性尿の
呈色と、人アルブミンあるいはγ−グロブリンを
添加した尿の呈色とを対比させ調べた。
[Industrial Field of Application] The present invention relates to a test piece for measuring protein, particularly urinary protein. [Background of the Invention] It is said that even healthy people excrete 20 to 80 mg of protein in the urine every day, and the excreted protein is usually mainly albumin, which has small particles and easily passes through the glomerulus. On the other hand, if hemolysis is severe and a large amount of hemoglobin from red blood cells leaks into the plasma and this leaks from the renal glomerulus, or if there is inflammation in the kidneys or urinary tract, white blood cells are released into the urine, so globulin is the main component. This results in urine protein. Urine protein generally becomes high in the following cases and is an important indicator of kidney disease. (1) Acute and chronic nephritis, nephrosis. (2) Renal congestion due to heart failure, etc. (3) Febrile proteinuria. (4) Chemical poisoning, bacterial poisoning. (5) Leukemia, purpura. (6) Stricture, stone Obstruction of the ureter due to tumor. (7) Brain tumors, epilepsy, other central nervous system diseases, and mental disorders. (8) Contamination with pus, blood, semen, etc. (9) Intake of large amounts of low molecular weight proteins such as eggs. (10) A temporary condition that appears after strenuous exercise or prolonged exposure to hot or cold water. (11) Postural and juvenile proteinuria. Currently, the following methods are commonly used for measuring urine protein. (1) Sulfosalicylic acid method (sensitivity 0.002%) Clear urine 4-5ml + sulfosalicylic acid 20W/V%
2-3 drops of solution → If white turbidity or precipitation occurs, it is protein positive. (2) Boiling test method (sensitivity approx. 0.005%) Boil 5 ml of clear urine for 1 to 2 minutes. If turbidity occurs, add 1 to 3 drops of 5% acetic acid or 70% nitric acid when hot, and remove the turbidity. If unchanged or increased, protein is positive. (3) Robers method (sensitivity 0.003%) If the sample and a nitric acid solution of magnesium sulfate are mixed in equal volumes and a white ring forms at the interface, it is positive for protein. (4) Test paper method (sensitivity 0.03%) This method uses a protein error method in which pH indicators such as bromophenol blue or tetrabromophenol blue develop an alkaline color due to the presence of protein. (5) Coomassie brilliant blue method (sensitivity 0.001%) A highly sensitive measurement method that uses the binding of dye and protein.
50 μ + 3 ml of CBB-G250 solution → Measure the absorbance at 595 nm. (6) Biuret method using trichloroacetic acid precipitation Mix 2 ml of sample (original urine) + 2 ml of distilled water + trichloroacetic acid (10% solution), centrifuge at 3000 rpm for at least 5 minutes, and then discard the supernatant. Biuret's reagent (NaOH4
%, potassium sodium tartrate crystals 4.5%,
CuSO 4.5H 2 O 0.5%, potassium iodide 0.5%)
After mixing 2 ml + 2 ml of distilled water, heat at 37℃ for 30 minutes.
Colorimetric at 540nm. Among these, the sulfosalicylic acid method, the boiling test method, and the Robers method require a large amount of sample by nephelometric method or a method similar thereto, and there are limits to their accuracy when applied to quantitative analysis. On the other hand, the Coomassie Brilliant Blue method is a colorimetric method, but it is considered unsuitable for continuous processing of a large number of samples because of the curvature of the calibration curve and the contamination of cells, test tubes, etc. Furthermore, the Biuret method using trichloroacetic acid precipitation requires a precipitation separation operation, which is complicated and impractical. In addition, although the test strip method using the protein error method is very simple and widely used, it has low sensitivity and is particularly difficult to judge between normal and abnormal. The drawback was that the coloration was extremely low. On the other hand, according to Analytical Chemistry Vol. 32 379-386 (1983), when protein (albumin) is added to a mixture of pyrogallol red and molybdate (PR-molybdenum complex), λmax shifts to the longer wavelength side and the protein is increased. There is a description that it is possible to perform colorimetric determination with sensitivity. However, when protein concentration is measured using the reagent described in the literature as a sample in the urine of a healthy person (negative by the sulfosalicylic acid method), the absorbance of most samples is lower than that of the reagent blank, and a negative value is calculated as the protein concentration. Encounter a phenomenon. Therefore, it is completely impossible to apply this method as it is to the measurement of urine protein using human urine samples as a sample, and there is a current need for a simple, highly sensitive, and highly accurate method for measuring urine protein. be. [Object of the Invention] In view of the above-mentioned current situation, the present invention aims to provide a simple, highly sensitive, and highly accurate method for measuring urine protein.
This was developed for the purpose of practical application of a urine protein measurement method using a urine dipstick method using molybdate and a dye that forms a complex with molybdenum and whose wavelength shifts in the presence of protein. [Configuration of the Invention] The present invention provides a molybdate, a dye that forms a complex with molybdenum, and whose wavelength shifts due to the presence of a protein, and a chelating agent that binds to molybdenum, or a dye that does not react with the dye, and which A test for protein measurement consisting of an absorbent carrier impregnated with a composition for protein measurement consisting of a buffer and a metal ion capable of binding to oxalic acid, citric acid, phosphoric acid, and their salts, which are expected to coexist in the carrier. This is a piece of invention. That is, as a result of extensive research into the practical application of a method for measuring urine protein that uses a dye that forms a complex with molybdenum and whose wavelength shifts due to the presence of protein, the present inventors have found that a method for measuring urine protein that uses a dye that forms a complex with molybdenum and whose wavelength shifts due to the presence of protein has been developed. Either a chelating agent capable of binding molybdenum is added to the measurement reagent in advance, or it does not react with the dye,
Oxalic acid, citric acid, which are expected to coexist in the sample,
The purpose can be achieved by adding phosphoric acid and metal ions that can bind with these salts, and it can be easily achieved by using a test piece consisting of a carrier (reagent holding piece) impregnated with such a reagent composition. The inventors have now completed the present invention by discovering that it is possible to measure urine protein with high sensitivity and precision. The present invention utilizes the fact that pigments such as pyrogallol red and pyrocatechol violet form complexes with molybdenum, and that this complex binds to proteins and shifts the maximum absorption wavelength to the long wavelength side. When measuring protein using the test strip method, chelating agents that are present in the sample and cause the color to fade, such as organic acids and/or phosphates, or chelating agents that have the same effect as these, must be used. The impregnating reagent contains metal ions that have been added in advance to the impregnating reagent, or can bind to oxalic acid, citric acid, phosphoric acid, and salts thereof that do not react with the dye and are expected to coexist in the sample. By adding globulin to albumin, it is possible to avoid the phenomenon in which the color of normal urine fades, and to measure urinary protein with extremely high accuracy. This makes it possible to measure. In other words, pigments such as pyrogallol red and pyrocatechol violet form complexes with molybdenum and become colored (or their coloring increases), but when other chelating agents that have binding strength with molybdenum coexist, some of the molybdenum is The moiety separates from its binding with these pigments and binds with other chelating agents, resulting in a dimming of the blind coloration. As the chelating agent is gradually added to the impregnating reagent, the color of the blind test will gradually become lighter depending on the amount added, and beyond a certain amount, even if the chelating agent derived from the sample is mixed in, it will no longer be that color. The phenomenon in which the coloration becomes lighter is hardly observed, and the coloration becomes less pale. Similarly, when aluminum ions, cerium ions, etc. are added to the impregnating reagent, the chelating agents (oxalic acid, citric acid, phosphoric acid, etc.) in the sample bind aluminum ions, cerium ions, etc. and do not bind to molybdenum ( (or the binding ratio decreases), and it is possible to avoid the color from becoming pale. Therefore, by adding in advance a chelating agent capable of binding to molybdenum or metal ions such as aluminum ions and cerium ions to the measurement composition, the phenomenon in which the color of normal urine becomes too pale can be resolved. At the same time, accurate measurement is possible even when measuring a sample containing a high concentration of protein using a reagent containing a chelating agent that binds to molybdenum, aluminum ions, cerium ions, etc. The present inventors discovered a previously unexplained cause of negative values in normal urine in a urine protein measurement method that uses a dye that forms a complex with molybdenum and whose wavelength shifts in the presence of protein. We investigated the
As a solution to this problem, the present inventors drew the above conclusion based on their own knowledge and arrived at the present invention. According to the method of the present invention, the coloration of normal urine does not become too pale, and both quantitative performance and reproducibility are good. Furthermore, since the test piece for protein measurement of the present invention is highly sensitive, it can be used to detect the borderline between normal and abnormal (protein concentration 10 to 30 mg / dl) became clearer and easier to judge. In addition, in the conventional protein error method, the coloration of globulin relative to albumin was extremely low;
In the method of the present invention, globulin is colored to almost the same extent as albumin, making it possible to detect globulinuria, which may have been overlooked by conventional test strip methods. As the chelating agent used in the present invention,
Ethylenediaminetetraacetic acid (EDTA), hydroxyethylethylenediaminetriacetic acid (EDTA-OH),
Ethylenediaminediacetic acid (EDDA), iminodiacetic acid (IDA), nitrilopropionic acid (NTP), nitrilotriacetic acid (NTA), hydroxyethyliminodiacetic acid (HIDA), citric acid, tartaric acid, oxalic acid, 1-hydroxyethane-1 , 1-diphosphonic acid, pyrophosphoric acid, hexametaphosphoric acid, tripolyphosphoric acid, metaphosphoric acid and the like. These may be used alone or in a mixture of two or more, and in order to improve the dissolution process when preparing the impregnating solution, they may be added in the form of salts such as alkali metal salts such as sodium, potassium, and lithium, or ammonium salts. It's okay. The amount added varies depending on the chelating agent added, but it is usually impregnated into an absorbent carrier such as paper or nonwoven fabric in one to several portions at a concentration of 0.001 to 1%. Also, suitable metal ions that can be used in the present invention include aluminum ions and cerium ions. Dyes that can be used in the present invention include pyrogallol red (PR), brompyrogallol red, pyrocatechol violet (PV), and o-hydroxyhydroxy nymph, which quantitatively form a complex with albumin in the presence of molybdenum. Examples include pigments such as talen and gallein. The amount of these pigments used is usually 0.0005 to 0.1 as the concentration of the impregnating solution.
%, and may be impregnated into an absorbent carrier such as paper or nonwoven fabric in one to several portions. Molybdenum that forms a complex with these pigments is usually used as an aluminum salt or an alkali metal salt of molybdic acid, but is not limited to these. For example, in the case of molybdate, the concentration of molybdate ion in the impregnating solution is usually about 0.0005 to 0.1%.
The absorbent carrier can be impregnated in one to several batches. Absorbent carriers used in the test strip for protein measurement of the present invention include, without exception, absorbent carriers used in ordinary test strips for measurement, such as paper, cellulose, chemical fibers, synthetic resin woven fabrics, and non-woven fabrics. used. In addition, as a support for holding an absorbent carrier,
Examples include glass fiber, and synthetic polymer compounds such as polyvinyl chloride, polystyrene, polyvinyl acetal, acetylcellulose, nitrocellulose, polyvinylidene chloride, and polypropylene, and sheets of these or coated cardboard are preferably used. There are no particular restrictions on the size, dimensions, etc. of these absorbent carriers and supports, and as long as they are used in accordance with the size and dimensions of the absorbent carriers and supports in commonly used measurement test pieces. Enough. Regarding the method of impregnating the drug into the absorbent carrier and the method of adhering the absorbent carrier to the support, any method used for ordinary measurement test pieces may be used, or special methods may be used. No method required. Table 1 shows the effect of adding a chelating agent in the method of the present invention. The measurement conditions are as follows. Measurement conditions Sample urine Protein negative (by sulfosalicylic acid method) Urine A,
B and C contain human albumin or human γ-globulin.
The sample was added at a concentration of 20 mg/dl. Impregnation liquid: Concentration of pyrogallolred 250mg/, sodium molybdate 300mg/
It was dissolved in 0.5M glycine-hydrochloric acid buffer (PH2.5). Method for Preparing Test Pieces Various chelating agents were added to the above impregnating solution at the concentrations shown in the table, and paper with a thickness of 0.4 mm was impregnated with this and dried. The test paper thus obtained was cut into 5 mm squares and attached to one end of a 5 mm x 8 cm polyvinyl chloride sheet using double-sided adhesive tape to form a test piece. Measurement method This test piece was momentarily immersed in sample urine, and the color development after 60 seconds of impregnation was measured. The coloration was investigated by comparing the coloration of negative urine and the coloration of urine to which human albumin or γ-globulin had been added.
【表】【table】
【表】
表1より明らかな如く、キレート剤の添加によ
り、試験紙は、尿中の蛋白によつて呈色し、蛋白
の測定が可能となることが判る。
また、表2に本発明の方法に於けるアルミニウ
ムイオン及びセリウムイオンの添加効果を示す。
尚、測定条件は下記の通りである。
測定条件
検体尿
表1の場合と同じ。
含浸液
表1の場合と同じ。
試験片の作製法
上記含浸液に酢酸セリウム(0.05%)又は硫酸
アルミニウム(0.05%)を添加し、これを厚さ
0.4mmの紙に含浸させ乾燥した。このようにし
て得られた試験紙を5mm角に切断し、両面接着テ
ープを用いて5mm×8cmのポリ塩化ビニルシート
の一端に貼り付け試験片とした。
測定方法
表1の場合と同じ。[Table] As is clear from Table 1, the addition of the chelating agent causes the test strip to change color due to the protein in the urine, making it possible to measure protein. Further, Table 2 shows the effect of adding aluminum ions and cerium ions in the method of the present invention.
The measurement conditions are as follows. Measurement conditions Sample urine Same as in Table 1. Impregnation liquid Same as in Table 1. Preparation method of test piece Add cerium acetate (0.05%) or aluminum sulfate (0.05%) to the above impregnating solution, and add this to the thickness
It was impregnated onto 0.4 mm paper and dried. The test paper thus obtained was cut into 5 mm squares and attached to one end of a 5 mm x 8 cm polyvinyl chloride sheet using double-sided adhesive tape to form a test piece. Measurement method: Same as in Table 1.
実施例 1
(1) 含浸液の調製
ピロガロールレツド 25mg
モリブデン酸アンモニウム 30mg
シユウ酸 300mg
グリシン 3.75g
塩化ナトリウム 3g
これらを水90mlに溶解して、塩酸でPH2.5とし、
全量を100mlとした。
(2) 試験片の作製
クトマト用紙(厚さ0.4mm)に上記含浸液を
含浸させ、乾燥した。このようにして作製した試
験片を5mm角の正方形に切断し、両面接着テープ
を用いてポリ塩化ビニルシート(5mm×8cm)に
貼り付け試験片とした。
(3) 測定方法及び測定結果
検体尿に試験片を瞬時浸漬しこれを含浸させた
後、約1分後の呈色をみた。蛋白濃度に応じて試
験紙部分は青紫〜青色に呈色した。検出限界は、
10mg/dlであつた。
実施例 2
(1) 含浸液の調製
ピロガロールレツド 25mg
モリブデン酸アンモニウム 30mg
クエン酸 600mg
グリシン 3.75g
塩化ナトリウム 2g
これらを水90mlに溶解して、塩酸でPH2.5とし、
全量を100mlとした。
(2) 試験片の作製
実施例1と同様にして試験片を作製した。
(3) 測定方法及び測定結果
実施例1と同様にして測定を行い同様の結果が
得られた。
実施例 3
(1) 含浸液の調製
ピロガロールレツド 25mg
モリブデン酸アンモニウム 30mg
EDTA・2Na 100mg
グリシン 3.75g
これらを水90mlに溶解して、塩酸でPH2.5とし、
全量を100mlとした。
(2) 試験片の作製
実施例1と同様にして試験片を作製した。
(3) 測定方法及び測定結果
実施例1と同様にして測定を行い実施例1と同
様の結果が得られた。
実施例 4
(1) 含浸液の調製
ピロカテコールバイオレツト 10mg
モリブデン酸アンモニウム 30mg
EDTA・2Na 100mg
グリシン 3.75g
塩化カリウム 2g
これらを水90mlに溶解して、塩酸でPH2.5とし、
全量を100mlとした。
(2) 試験片の作製
実施例1と同様にして試験片を作製した。
(3) 測定方法及び測定結果
検体尿に試験片を瞬時浸漬してこれを含浸させ
た後、約1.5分後の呈色をみた。蛋白濃度に応じ
て試験紙部分は緑色に呈色した。検出限界は、10
mg/dlであつた。
〔発明の効果〕
以上述べた如く、本発明は蛋白、特に尿蛋白の
試験紙法による改良された測定法を提供するもの
であり、簡便且つ高感度、高精度の蛋白測定法で
あると共に従来の蛋白誤差法による試験紙法と異
なり、γ−グロブリンの検出も可能な測定法であ
る点に顕著な効果を奏する発明であつて斯業に貢
献するところ極めて大なる発明である。
Example 1 (1) Preparation of impregnating solution Pyrogallol red 25mg Ammonium molybdate 30mg Oxalic acid 300mg Glycine 3.75g Sodium chloride 3g Dissolve these in 90ml of water, adjust the pH to 2.5 with hydrochloric acid,
The total volume was 100ml. (2) Preparation of test piece Kutomato paper (thickness 0.4 mm) was impregnated with the above impregnation liquid and dried. The thus prepared test piece was cut into a 5 mm square, which was attached to a polyvinyl chloride sheet (5 mm x 8 cm) using double-sided adhesive tape to form a test piece. (3) Measurement method and measurement results After the test piece was momentarily immersed in the sample urine and impregnated, color development was observed about 1 minute later. The test paper portion was colored from bluish-purple to blue depending on the protein concentration. The detection limit is
It was 10mg/dl. Example 2 (1) Preparation of impregnating solution Pyrogallol red 25mg Ammonium molybdate 30mg Citric acid 600mg Glycine 3.75g Sodium chloride 2g Dissolve these in 90ml of water, adjust the pH to 2.5 with hydrochloric acid,
The total volume was 100ml. (2) Preparation of test piece A test piece was prepared in the same manner as in Example 1. (3) Measurement method and measurement results Measurement was carried out in the same manner as in Example 1, and the same results were obtained. Example 3 (1) Preparation of impregnating solution Pyrogallol Red 25mg Ammonium Molybdate 30mg EDTA・2Na 100mg Glycine 3.75g Dissolve these in 90ml of water and adjust the pH to 2.5 with hydrochloric acid.
The total volume was 100ml. (2) Preparation of test piece A test piece was prepared in the same manner as in Example 1. (3) Measurement method and measurement results Measurement was carried out in the same manner as in Example 1, and the same results as in Example 1 were obtained. Example 4 (1) Preparation of impregnation solution Pyrocatechol violet 10mg Ammonium molybdate 30mg EDTA・2Na 100mg Glycine 3.75g Potassium chloride 2g Dissolve these in 90ml of water, adjust the pH to 2.5 with hydrochloric acid,
The total volume was 100ml. (2) Preparation of test piece A test piece was prepared in the same manner as in Example 1. (3) Measurement method and measurement results After the test piece was momentarily immersed in the sample urine to impregnate it, color development was observed about 1.5 minutes later. The test paper area turned green depending on the protein concentration. The detection limit is 10
It was mg/dl. [Effects of the Invention] As described above, the present invention provides an improved method for measuring protein, especially urine protein, using a test strip method. Unlike the test strip method based on the protein error method described above, this invention has a remarkable effect in that it is a measuring method that can also detect γ-globulin, and it is an extremely significant invention that contributes to this industry.
Claims (1)
形成し、さらに蛋白の存在で波長がシフトする色
素と、モリブデンと結合するキレート剤、又は
前記色素とは反応せず、試料中に共存が予想され
るシユウ酸、クエン酸、リン酸及びこれらの塩と
結合し得る金属イオンと、緩衝剤とから成る蛋
白測定用組成物を含有させた吸収性担体から成る
蛋白測定用試験片。 2 蛋白が尿蛋白である、特許請求の範囲第1項
記載の試験片。 3 キレート剤が、エチレンジアミン四酢酸
(EDTA)、ヒドロキシエチルエチレンジアミン
三酢酸(EDTA−OH)、エチレンジアミン二酢
酸(EDDA)、イミノニ酢酸(IDA)、ニトリロプ
ロピオン酸(NTP)、ニトリロ三酢酸(NTA)、
ヒドロキシエチルイミノ二酢酸(HIDA)、クエ
ン酸、酒石酸、シユウ酸、1−ヒドロキシエタン
−1,1−ジホスホン酸、ピロリン酸、ヘキサメ
タリン酸、トリポリリン酸、メタリン酸、及びこ
れらの塩類の内の1種又は2種以上である特許請
求の範囲第1項又は第2項記載の試験片。 4 金属イオンがアルミニウムイオン又は/及び
セリウムイオンである特許請求の範囲第1項又は
第2項記載の試験片。 5 色素がピロガロールレツド又はピロカテコー
ルバイオレツトである特許請求の範囲第1項〜第
4項のいずれかに記載の試験片。[Claims] 1. A molybdate, a dye that forms a complex with molybdenum and whose wavelength shifts due to the presence of protein, and a chelating agent that binds to molybdenum, or a chelating agent that does not react with the dye and is present in the sample. A test piece for measuring protein comprising an absorbent carrier containing a composition for measuring protein comprising a buffer and a metal ion capable of binding with oxalic acid, citric acid, phosphoric acid and salts thereof, which are expected to coexist. 2. The test piece according to claim 1, wherein the protein is urinary protein. 3 The chelating agent is ethylenediaminetetraacetic acid (EDTA), hydroxyethylethylenediaminetriacetic acid (EDTA-OH), ethylenediaminediacetic acid (EDDA), iminodiacetic acid (IDA), nitrilopropionic acid (NTP), nitrilotriacetic acid (NTA),
Hydroxyethyliminodiacetic acid (HIDA), citric acid, tartaric acid, oxalic acid, 1-hydroxyethane-1,1-diphosphonic acid, pyrophosphoric acid, hexametaphosphoric acid, tripolyphosphoric acid, metaphosphoric acid, and one of these salts or 2 or more types of test pieces according to claim 1 or 2. 4. The test piece according to claim 1 or 2, wherein the metal ions are aluminum ions and/or cerium ions. 5. The test piece according to any one of claims 1 to 4, wherein the dye is pyrogallol red or pyrocatechol violet.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14625285A JPS626170A (en) | 1985-07-03 | 1985-07-03 | Test piece for measuring protein |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14625285A JPS626170A (en) | 1985-07-03 | 1985-07-03 | Test piece for measuring protein |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS626170A JPS626170A (en) | 1987-01-13 |
JPH0564745B2 true JPH0564745B2 (en) | 1993-09-16 |
Family
ID=15403535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14625285A Granted JPS626170A (en) | 1985-07-03 | 1985-07-03 | Test piece for measuring protein |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS626170A (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5055407A (en) * | 1988-07-05 | 1991-10-08 | Miles, Inc. | Composition and method of assaying aqueous liquids for specific gravity |
US5281662A (en) * | 1988-08-03 | 1994-01-25 | New England Deaconess Hospital Corporation | Anthraquinone dye treated materials |
EP0592674B1 (en) * | 1991-12-25 | 2000-11-29 | Iatron Laboratories, Inc. | Method of assaying metal present in biological specimen and reagent therefor |
US5925570A (en) * | 1991-12-25 | 1999-07-20 | Iatron Laboratories, Inc. | Method of measuring metals in samples of living body |
WO1996030764A1 (en) * | 1995-03-24 | 1996-10-03 | Vorwerk & Co. Interholding Gmbh | Method of examining household dust |
CA2236350C (en) * | 1997-05-06 | 2007-05-15 | Thomas Arter | Dry analytical elements for the determination of protein |
JP4894445B2 (en) * | 2006-10-10 | 2012-03-14 | Jnc株式会社 | Calcium quantification method and calcium quantification kit |
US7745153B2 (en) * | 2008-02-06 | 2010-06-29 | Pierce Biotechnology, Inc. | Pyrocatechol violet-metal protein assay |
CN102680701A (en) * | 2012-04-27 | 2012-09-19 | 嘉兴九七九生物技术有限公司 | Quantitative detection reagent and quantitative detection method for urinary protein liquid |
CN110095457A (en) * | 2019-04-17 | 2019-08-06 | 广东环凯微生物科技有限公司 | A kind of the measurement test paper and rapid assay methods of chlorine residue |
-
1985
- 1985-07-03 JP JP14625285A patent/JPS626170A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS626170A (en) | 1987-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fowden | The quantitative recovery and colorimetric estimation of amino-acids separated by paper chromatography | |
Kessler et al. | An automated procedure for the simultaneous determination of calcium and phosphorus | |
Pesce et al. | A new micromethod for determination of protein in cerebrospinal fluid and urine | |
EP1715347B1 (en) | Method of protein measurement | |
US7785892B2 (en) | Method of determining iron concentration | |
US5397710A (en) | Process for measuring magnesium in biological fluids | |
JPH0564745B2 (en) | ||
JP2004138408A (en) | Specimen for measuring creatinine | |
JPS61247969A (en) | Method of analyzing calcium and reagent for analysis thereof | |
US4448889A (en) | Fluid analysis | |
JPH07209304A (en) | Composition for analysis of protein in urine and measurement thereof | |
US4529708A (en) | Assay for the determination of creatinine | |
JP2749615B2 (en) | Novel indicator compounds, their preparation and use of the compounds in iron analysis systems | |
JPH0453265B2 (en) | ||
JP2000193668A (en) | Composition for measuring trace amount of protein | |
SUTOR et al. | Urinary inhibitors of the formation of calcium oxalate | |
Valcour et al. | Proposed reference method for iron in serum used to evaluate two automated iron methods | |
US4278440A (en) | Reagent and method for direct determination of chloride in serum | |
JPH07218511A (en) | Method for measuring iron and reagent thereof | |
CA2236350C (en) | Dry analytical elements for the determination of protein | |
JP3220378B2 (en) | Method and reagent for quantification of total protein | |
JP2632989B2 (en) | Method for measuring unsaturated iron binding ability | |
CN111830259B (en) | Alpha 1 microglobulin determination kit | |
US3201202A (en) | Diagnostic procedure | |
JPH0635974B2 (en) | Test piece for protein measurement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EXPY | Cancellation because of completion of term |